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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Angiotensin II receptor 
blocker-mediated 
acute fall in glomerular 
filtration rate may be 
good for you
There is general resistance to the use of 
angiotensin-converting enzyme inhibitors 
or angiotensin II receptor blockers by 
residents who claim that such use could 
reduce renal function. The contention that 
this is a physiological effect, and might 
even be beneficial, somehow never satis-
fies the doubters. In this issue, Holtkamp 
et al. finally provide us with the best data 
on the subject. They performed a post hoc 
analysis of the RENAAL trial, in which 
losartan was used for treatment of non-
insulin-dependent diabetes mellitus, and 
found that treated patients had a greater 
acute fall in estimated glomerular filtration 
rate (eGFR) during the first 3 months of 
therapy that was quite variable. The authors 
divided the patients into tertiles based on 
the extent of the acute fall in eGFR. They 
found that the long-term slope of the eGFR 
(the rate of progression of chronic kidney 
disease) gave some interesting results; the 
greater the initial fall in eGFR, the less 
the chronic kidney disease progressed. 
See page 282.
Progesterone and 
potassium depletion
The role that female sex hormones play in 
regulation of renal function is an under-
studied field. Elabida et al. provide a novel 
approach. First, they use a mathemati-
cal model that suggested that potassium 
depletion might stimulate progesterone 
production. Regardless of whether one 
believes in the utility of these models, 
the proof was provided by the fact that 
potassium depletion in mice and humans 
showed an increase in progesterone levels. 
The authors then show that progesterone 
indeed stimulates renal potassium absorp-
tion. Again, they provided a novel insight 
into this process by showing that the non-
gastric hydrogen, potassium–ATPase is 
stimulated, which provides a molecular 
and even systemic explanation for the long-
known observation that chronic potassium 
depletion stimulates potassium absorption 
in the distal nephron. See page 256.
Tolvaptan in autosomal 
dominant polycystic 
kidney disease
One of the more interesting developments in 
the polycystic kidney disease field concerns 
the finding that many, if not most, cysts 
originate from the collecting duct and have 
V2 vasopressin receptors. Stimulation by the 
hormone leads to accumulation of cyclic 
adenosine 3ʹ,5ʹ-monophosphate (cAMP) 
and, with it, activation of secretion into the 
cyst. Several animal studies used the newly 
developed receptor antagonists to show that 
the progression of cysts was slowed. In this 
issue, Irazabal et al. present the initial study 
on the effect of short-term use of tolvaptan 
on renal function and cyst size in humans. 
They found in 20 patients with autosomal 
dominant polycystic kidney disease that 
there was, as expected, an initial water diu-
resis and a significant fall in glomerular 
filtration rate. An analysis of cyst size by 
magnetic resonance imaging showed a sig-
nificant reduction in cyst size after 1 week of 
treatment. Though the reduction in size was 
modest, amounting to 1.6% of individual 
cyst volumes, these changes were statistically 
significant. That there was such an effect after 
only 1 week of treatment suggests that the 
purported mechanism of action, reduction 
of cAMP, and hence secretion, might well be 
true. See page 295.
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